Testing a new add-on medication for schizophrenia that doesn't respond to standard treatment

Plain-English translation of NCT07184619 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called evenamide as an add-on treatment for people with treatment-resistant schizophrenia—a form of the condition that doesn't respond adequately to standard antipsychotic medications. You would take the medication (or a placebo) for 12 weeks alongside your current antipsychotic to see if it helps reduce your symptoms. About 400 people will participate, with half receiving the new treatment and half receiving a placebo.

Many people with schizophrenia don't get enough symptom relief from standard antipsychotic medications alone. This trial is exploring whether adding this medication could help people in that situation feel better and have more control over their symptoms.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with schizophrenia
your symptoms have not improved enough despite taking a stable dose of one or more antipsychotic medications
you are currently taking at least a minimum effective dose of antipsychotic medication and have been stable on it
you agree to use reliable contraception (if female and able to become pregnant)

You likely don't qualify if…

you have a different primary psychiatric diagnosis, such as schizoaffective disorder, bipolar disorder, or major depression
you have used illegal drugs or misused prescription drugs in the past three months
you have attempted suicide within the past two years or are currently at significant risk
you have a history of seizures or epilepsy
you have had neuroleptic malignant syndrome or certain other serious medical conditions that could affect your safety in the study

What participation looks like

You would visit the research site to receive either evenamide or a placebo capsule to take twice daily for 12 weeks, in addition to your current antipsychotic medication. The researchers would check in with you regularly to see how you're doing, measure any changes in your symptoms, and watch for any side effects. You won't know whether you're receiving the new medication or a placebo—that's what makes it a 'blinded' study—but the research team will know if they need to help you for safety reasons.

AI-generated summary from trial data · Jul 2, 2026 · Not medical advice

Trial locations(15 sites)

United States

UCLA DGSOM, UCLA Health, UCLA Semel Institute, Los Angeles, California

University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital, Miami, Florida

Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research, New York, New York